CTL019
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Lymphoblastic Leukemia
Conditions
Acute Lymphoblastic Leukemia
Trial Timeline
Apr 24, 2017 → Oct 13, 2020
NCT ID
NCT03123939About CTL019
CTL019 is a phase 3 stage product being developed by Novartis for Acute Lymphoblastic Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03123939. Target conditions include Acute Lymphoblastic Leukemia.
What happened to similar drugs?
20 of 20 similar drugs in Acute Lymphoblastic Leukemia were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03601442 | Pre-clinical | Active |
| NCT04161118 | Phase 2 | Terminated |
| NCT04094311 | Phase 3 | Recruiting |
| NCT03876769 | Phase 2 | Active |
| NCT03123939 | Phase 3 | Completed |
| NCT02435849 | Phase 2 | Completed |
Competing Products
20 competing products in Acute Lymphoblastic Leukemia